文献速递贫血与红细胞疾病

全人源抗BMP6抗体减少慢性病贫血啮齿动物模型对促红细胞生成素的需求

A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease.
PubMed 文献 · Blood · 2020-01-01

研究在两种慢性病贫血啮齿动物模型中评估全人源抗BMP6抗体KY1070单用或联合达依泊汀α对铁代谢和贫血的作用。结果显示联合治疗在定性和定量上均优于任一单药,并产生促红细胞生成素节省效应;KY1070通过抑制铁调素调节红系前体细胞膜铁转运蛋白表达,降低潜在毒性游离细胞内铁并加速红细胞生成。

要点

  • KY1070联合达依泊汀α较任一单药在定性和定量上改善红系反应。
  • KY1070联合达依泊汀α产生促红细胞生成素节省效应。
  • KY1070抑制铁调素,调节红系前体细胞膜铁转运蛋白表达并加速红细胞生成。

核心结论

  • 慢性病贫血作为高度复杂疾病,通过动员内源性铁储存和刺激红细胞生成的多因素治疗策略可提高疗效。

研究设计与样本

  • 在两种不同、成熟且临床相关的慢性病贫血啮齿动物模型中评估全人源抗BMP6抗体KY1070单用或联合达依泊汀α对铁代谢和贫血的作用。

主要发现

  • KY1070联合重组人促红细胞生成素较任一单药在定性和定量上改善红系反应。
  • KY1070联合达依泊汀α产生促红细胞生成素节省效应。
  • KY1070抑制铁调素,调节红系前体细胞膜铁转运蛋白表达,降低潜在毒性游离细胞内铁水平。
  • KY1070通过加速红系输出使红细胞前体成熟增加。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recombinant erythropoietin (EPO) and iron substitution are a standard of care for treatment of anemias associated with chronic inflammation, including anemia of chronic kidney disease. A black box warning for EPO therapy and concerns about negative side effects related to high-dose iron supplementation as well as the significant proportion of patients becoming EPO resistant over time explains the medical need to define novel strategies to ameliorate anemia of chronic disease (ACD). As hepcidin is central to the iron-restrictive phenotype in ACD, therapeutic approaches targeting hepcidin were recently developed. We herein report the therapeutic effects of a fully human anti-BMP6 antibody (KY1070) either as monotherapy or in combination with Darbepoetin alfa on iron metabolism and anemia resolution in 2 different, well-established, and clinically relevant rodent models of ACD. In addition to counteracting hepcidin-driven iron limitation for erythropoiesis, we found that the combination of KY1070 and recombinant human EPO improved the erythroid response compared with either monotherapy in a qualitative and quantitative manner. Consequently, the combination of KY1070 and Darbepoetin alfa resulted in an EPO-sparing effect. Moreover, we found that suppression of hepcidin via KY1070 modulates ferroportin expression on erythroid precursor cells, thereby lowering potentially toxic-free intracellular iron levels and by accelerating erythroid output as reflected by increased maturation of erythrocyte progenitors. In summary, we conclude that treatment of ACD, as a highly complex disease, becomes more effective by a multifactorial therapeutic approach upon mobilization of endogenous iron deposits and stimulation of erythropoiesis.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Petzer V, Tymoszuk P, Asshoff M, et al. A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease. Blood. 2020. PMID: 32438400. doi:10.1182/blood.2019004653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。